<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878823</url>
  </required_header>
  <id_info>
    <org_study_id>3125001</org_study_id>
    <nct_id>NCT03878823</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of ODM-209</brief_title>
  <acronym>STESIDES</acronym>
  <official_title>Safety and Pharmacokinetics of ODM-209 in Patients With Metastatic Castration-resistant Prostate Cancer or Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study is to evaluate safety and tolerability of ODM-209
      and find the dose of ODM-209.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: to evaluate the safety and tolerability of ODM-209, to define the maximum tolerated
      dose (MTD) and dose limiting toxicities (DLTs) of ODM-209, if feasible, to define the
      recommended dose of ODM-209 and replacement therapy for Part 2 of the study.

      Part 2: to further evaluate the safety and tolerability of ODM-209, to evaluate the
      preliminary anticancer activity of ODM-209.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Within first 28 days of treatment</time_frame>
    <description>Highest dose level at which under 33% of patients in a cohort experience DLT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ODM-209 Part 1 Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-209 Part 2 Dose expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-209</intervention_name>
    <description>co-administered with glucocorticoid and mineralocorticoid, orally daily</description>
    <arm_group_label>ODM-209 Part 1 Dose escalation</arm_group_label>
    <arm_group_label>ODM-209 Part 2 Dose expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MAIN INCLUSION CRITERIA:

          -  Written informed consent (IC) obtained.

          -  Age ≥ 18 years.

          -  ECOG performance status 0-1.

          -  Adequate marrow, liver and kidney function.

          -  Able to swallow study treatment.

        Main Prostate cancer specific inclusion criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Castration resistant prostate cancer with serum testosterone &lt; 50 ng/dl.

          -  Metastatic disease.

          -  Ongoing androgen deprivation therapy with GnRH analogue, or have had bilateral
             orchiectomy.

          -  Have had treatment with at least one line of second generation androgen receptor
             targeting therapy and one line of chemotherapy.

        Main Breast cancer specific inclusion criteria:

          -  Histologically confirmed breast carcinoma

          -  ER positive, HER2-negative advanced breast cancer

          -  Postmenopausal or pre/perimenopausal if amendable to be treated with GnRH agonist or
             antagonist.

          -  Documented disease progression after treatment with at least 2 lines of systemic
             treatment for advanced breast cancer. Of these, at least one line must have been
             endocrine treatment in combination with a cdk4/6 inhibitor.

        MAIN EXCLUSION CRITERIA

          -  History of pituitary dysfunction.

          -  Known brain metastases or active leptomeningeal disease.

          -  Active infection or other medical condition that would make corticosteroids
             contraindicated.

          -  Hypotension or uncontrolled hypertension.

          -  Clinically significant cardiovascular disease, e.g. myocardial infarction, arterial
             thrombotic events, or pulmonary embolism in the past six months, unstable angina, or
             congestive heart failure (New York Heart Association [NYHA] class II-IV).

          -  Prolonged QTcF interval.

          -  Use of any investigational drug 4 weeks prior to the start of the study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta Hänninen</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orion Pharma Clinical Study Director</last_name>
    <phone>+358 10 426 7792</phone>
    <email>clinicaltrials@orionpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet, University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic castration-resistant prostate cancer</keyword>
  <keyword>advanced hormone receptor positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

